Arturo Soto

Arturo Soto

Auto-generated profile, based on publicly available information

Arturo Soto

Department of Clinical Pharmacology, PharmaMar, S.A., Avda. de los Reyes, 1 Colmenar Viejo, 28770, Madrid, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

20 May 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SFS. J. Faivre
S. J. Faivre
SRS. Ropert
S. Ropert
CCC. Coronado
C. Coronado
JAJ. Alcantara
J. Alcantara
BMB. De Miguel
B. De Miguel
EREric Raymond
Eric Raymond
E13097 Background: E is a new synthetic depsipetide with broad in vitro/in vivo antitumor activity. E induces cell death through profound alterations in the plasmatic membrane of tumor cells, while C targets the DNA in a cell cycle independent manner. In vitro experiments showed a synergistic effect between E and platinum compounds in different cell lines. Objectives: To identify the maximum tolerated dose (MTD) and the recommended dose (RD) of C given on day (d) 1 followed by E as a 3-hour i.v. infusion on d1 and d8, every three weeks, as well as safety and feasibility, pharmacokinetic analysis and antitumor activity. Methods: Pts with advanced solid tumors for whom no standard therapy is available were recruited. A classical 3+3 successive cohort escalation design was followed. Results: The median age of the 15 pts included was 59 (25-73) years, they had received a median 6 prior lines of therapy, and 10 were males. Main tumor types were colorectal and head and neck (n=4, each). After 3 evaluable pts we...